Ann: PTX-100 trial advances following successful Phase 1b, page-276

Hi Mason,

If we look at the announcement & the presentation from an agnostic point of view & focus on the facts.

PTX-100 had an excellent safety profile across the entire cohort. Considering safety was the primary focus of the study I think we can all agree ptx-100 performed as well as it possibly could .

As for efficacy, we know that 2/2 patients in the cohort had a response to ptx-100. It sounds like there were other responses from the mixed cohort however we will leave that at the door.

The 1B basket case study has helped management & Professor Miles of the Epworth/Peter Mac identify TCL cancer as the optimal target market to progress with in the expanded cohort.

That's about the crux of it, as a shareholder I think the report was positive reading and there is very good reason for optimism regarding the expanded cohort targeting TCL cancer.

The ptx-100 expanded cohort study results will be a very critical juncture for 'Prescient Therapeutics', company making if we can build on or replicate the initial TCL response from the initial mixed basket cohort study.

Will be very interesting to see what data is derived from the study in due time.